Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

teva b.v. - acide zolédronique - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - médicaments pour le traitement des maladies osseuses - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. le traitement de la maladie de paget de l'os chez les adultes.

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - natrii risedronas - comprimés pelliculés - natrii risedronas 5 mg, excipiens pro compresso obducto. - osteoporose, paget-krankheit - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - natrii risedronas - comprimés pelliculés - natrii risedronas 30.0 mg corresp. natrium 2.26 mg, lactosum monohydricum 131.0 mg, cellulosum microcristallinum, crospovidonum, magnesii stearas, Überzug: hypromellosum, macrogolum 400, hydroxypropylcellulosum, macrogolum 8000, silica colloidalis anhydrica, e 171, pro compresso obducto. - osteoporose, paget-krankheit - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - natrii risedronas - comprimés pelliculés - natrii risedronas 35.0 mg corresp. natrium 2.64 mg, lactosum monohydricum 126.0 mg, cellulosum microcristallinum, crospovidonum, magnesii stearas, Überzug: hypromellosum, macrogolum 400, hydroxypropylcellulosum, macrogolum 8000, silica colloidalis anhydrica, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto. - osteoporose, paget-krankheit - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - l'acide zoledronicum - solution à diluer pour perfusion - acidum zoledronicum 5 mg ut acidum zoledronicum monohydricum, mannitolum, natrii citras dihydricus corresp. natrium 7 mg, aqua ad iniectabile, ad solutionem pro 100 ml. - morbus paget, postmenopausale osteoporose - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

labatec pharma sa - l'acide zoledronicum - solution versez la perfusion - acidum zoledronicum 5 mg ut acidum zoledronicum monohydricum, mannitolum, natrii citras dihydricus, acidum hydrochloridum aut natrii hydroxidum, aqua ad iniectabile ad solutionem pro 100 ml corresp., natrium 7.21 mg. - morbus paget, ostéoporose postménopausique - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - l'acide zoledronicum - solution à diluer pour perfusion - acidum zoledronicum 5 mg ut acidum zoledronicum monohydricum, mannitolum, natrii citras dihydricus corresp. natrium 7 mg, aqua ad iniectabile, ad solutionem pro 100 ml. - morbus paget, postmenopausale osteoporose - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - l'acide zoledronicum - solution à diluer pour perfusion - acidum zoledronicum 5 mg ut acidum zoledronicum monohydricum, mannitolum, natrii citras dihydricus, aqua ad iniectabile ad solutionem pro 100 ml, natrium 8.02 mg. - morbus paget, postmenopausale osteoporose - synthetika

Kanada - Kifaransa - Health Canada

abbvie corporation - risédronate sodique (hémipentahydrate de risédronate sodique) - comprimé - 35mg - risédronate sodique (hémipentahydrate de risédronate sodique) 35mg - bone resorption inhibitors

Kanada - Kifaransa - Health Canada

auro pharma inc - risédronate sodique (hémipentahydrate de risédronate sodique) - comprimé - 5mg - risédronate sodique (hémipentahydrate de risédronate sodique) 5mg - bone resorption inhibitors